Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors

US11253560B2 · kind B2 · utility

Assignee

• Memorial Sloan Kettering Cancer Center · US

Inventors

• Liang Deng · New York, US
• Jedd D. Wolchok · New York, US
• Taha Merghoub · New York, US
• Stewart Shuman · New York, US
• Peihong Dai · New York, US
• Weiyi Wang · Hangzhou City, CN

Key dates

• Filing date: Jan 13, 2020
• Grant date: Feb 22, 2022
• Expiry date: Feb 26, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2710/24171
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAΔE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.